ARK Investment Management LLC Cuts Stock Position in Repare Therapeutics Inc. (NASDAQ:RPTX)

ARK Investment Management LLC lessened its stake in shares of Repare Therapeutics Inc. (NASDAQ:RPTX) by 20.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,999,997 shares of the company’s stock after selling 509,740 shares during the period. ARK Investment Management LLC’s holdings in Repare Therapeutics were worth $2,620,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in RPTX. Barclays PLC grew its stake in shares of Repare Therapeutics by 1,471.7% in the third quarter. Barclays PLC now owns 8,330 shares of the company’s stock worth $29,000 after acquiring an additional 7,800 shares during the last quarter. Vontobel Holding Ltd. raised its holdings in Repare Therapeutics by 45.8% in the fourth quarter. Vontobel Holding Ltd. now owns 35,000 shares of the company’s stock worth $46,000 after buying an additional 11,000 shares during the last quarter. Finally, Stifel Financial Corp lifted its stake in shares of Repare Therapeutics by 36.4% in the third quarter. Stifel Financial Corp now owns 51,700 shares of the company’s stock worth $178,000 after buying an additional 13,800 shares in the last quarter. Hedge funds and other institutional investors own 85.09% of the company’s stock.

Repare Therapeutics Trading Down 3.1 %

NASDAQ:RPTX opened at $1.25 on Thursday. The company has a market cap of $53.14 million, a PE ratio of -0.63 and a beta of 0.88. The company has a 50 day simple moving average of $1.27 and a two-hundred day simple moving average of $2.51. Repare Therapeutics Inc. has a 12 month low of $1.10 and a 12 month high of $7.45.

Analyst Ratings Changes

Several brokerages recently weighed in on RPTX. Lifesci Capital reissued a “market perform” rating on shares of Repare Therapeutics in a research report on Friday, December 13th. Stifel Nicolaus lowered their price target on Repare Therapeutics from $9.00 to $4.00 and set a “buy” rating on the stock in a report on Friday, December 13th. Bloom Burton cut Repare Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 10th. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Repare Therapeutics in a research report on Friday, November 8th.

About Repare Therapeutics

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.